Trends, Growing
Dr. Scott Chappel is the CSO of NextPoint Therapeutics, an MPM portfolio company, where he oversees the identification of antibodies against next-generation immune-oncology targets. If you breach any provision of these Terms, any license you have obtained will be automatically rescinded and terminated. available in electronic format on this webpage does not constitute an offer to sell or the
CAMBRIDGE, Mass. We will never disclose your PII to third parties for direct marketing purposes without your authorization. Bar on Crop Protection Safety Standards, UN
website. Provide sufficient information that allows us to reasonably verify you are the person about whom we collected personal information or an authorized representative. We may collect Person Information from you in a variety of ways: If you wish to exercise your rights under California law, please see the Right to Access and Control Your Personal Information Under the European Union Data Protection Regulation (GDPR) and CCPA section below for information on how to contact us to exercise your rights. He initiated newco research activities with Dr. Gordon Freeman out of the Dana-Farber Cancer Institute, pitching the science and partnering with . Announcements, Sustainability &
implemented in the Relevant Member State: provided that no such offer shall result in a requirement to publish a prospectus pursuant to
Viewing the materials you seek to access may not be lawful in certain jurisdictions. Republic, Dominican
The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. She has led pivotal studies demonstrating the utility of PD-L1 as a biomarker for efficacy of anti-PD1 agents in lung cancer as well as studies demonstrating the value of combining immunotherapy and chemotherapy in the treatment of non-small cell lung cancer. 25. Our innovative approach integrates foundational. Cancer Immunol Res. an offer to the public of the securities has not been made and will not be made in such Relevant
Any person who is not a relevant person should not act or rely on the
Further, it does not constitute a
Find out more: www.sanofiventures.com, Kira PeikoffLeaps by Bayer1(973)791-3348kira.peikoff@bayer.com. Bayer Global
Electronic materials such as music, videos, games, images and text in electronic form can easily be copied, modified and sent over networks (such as the internet). Published Jan. 12, 2023 By Kristin Jensen Courtesy of Sanofi Dive Brief: French drugmaker Sanofi is planning a multi-year capital infusion that will bring the total funding in its Sanofi Ventures evergreen fund to more than $750 million. They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. Slavery Act Statement, Position
NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Proc Natl Acad Sci U S A. Demand, Breakthroughs
Previous study start-up and clinical monitoring experience desired. Life & Challenges, Reputation
Statements, Reports
of Self-Care, Outperforming
The investment portfolio includes more than 50 companies. Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer. in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction, where
The final prospectus, when published, will be available on the website of
Zealand, Palestinian
Associate Director at Nextpoint Therapeutics Cambridge, Massachusetts, United States. Arab Emirates, United
Your computer and mobile devices when you access our Site. I have read and understood the disclaimer set out above. Nutrition
The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as
Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. Dr. Zang is professor of microbiology & immunology, of medicine, . NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. This time around, we note that NextPoint Therapeutics hired Leena Gandhi as chief medical officer. Bayer is an innovation company with a more than 150-year history. NextPoint's programs aim to deliver monotherapies for cancer patients without viable treatment options. Fighting Counterfeit Drugs, New Safety
2015 May 15;21(10):2359-66. We have no control over, do not review, and are not responsible for Third-Party Sites, their content, or any goods or services available through the Third-Party Sites. In Dr. Gandhis next role as Vice President of Immuno-Oncology Development at Eli Lilly, she led the development of novel immuno-oncology agents across cancer types before returning to Dana-Farber in 2020, where she most recently served as the Director of the Center for Cancer Therapeutic Innovation a cross-malignancy novel therapeutics hub. Leaps by Bayer and Sanofi Ventures led the round for the Cambridge, Massachusetts-based company. on
Fraudulent Brands, Commitment to
Africa, Sri
While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments,. relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. Where we are processing your Personal Data, subject to applicable law, you also have the right to: To exercise your rights, you may contact us as atinfo@nextpointtx.com. Experienced Management / Operations professional with a demonstrated history of working in the Biotech / Pharma industry and academic research. Jan 10, 2023. www.precisiononcologynews.com . 51373 Leverkusen
Expertise, Our
Briggs Morrison, MD, will step down as Interim CMO, but will continue to advise the company on an ongoing basis., I look forward to working with the NextPoint team to accelerate the development of programs targeting the HHLA2 pathway, a novel tumor-suppressive mechanism with the potential to impact many patients, commented Dr. Gandhi. To learn more, visit, Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. An
Only you or a person registered with the California Secretary of State that you authorize to act on your behalf, may make a verifiable consumer request related to your personal information. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. investment decision regarding the securities referred to herein should only be made on the basis
Phone:
Upload, email or otherwise transmit any images or other content that is unlawful, obscene, harmful, hateful, invades the privacy of any third party, contains nudity or pornography or is otherwise objectionable. We are currently looking to add a Vice President Translational Science to our fast moving, roll-up your sleeves team environment. interstate or foreign commerce, or of any facility of a national securities exchange of the United
Information, Analyst
I am currently pursuing a M.Sc. Republic, Ireland, Republic
Bayers leadership in agriculture provides tailored solutions
investor to decide to purchase any securities, as the same may be varied in that Relevant Member
We do not accept any responsibility or liability for these policies and procedures. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. Both programs of the Boston-based company use the recently . Feel free to contact me at Joash.tan.kiat@gmail.com or +65 97857618! 2021 Jul 9;6(61):9792. State. Personal Information does not include publicly available information, information that is de-identified, aggregated information, or any other information outside the scope of the California Consumer Privacy Act of 2018 (CCPA). NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Get the latest business insights from Dun & Bradstreet. Germany
Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer." Description Source: VentureRadar Research / Company Website Copyright 2022 NextPoint Therapeutics, Inc. All Rights Reserved. Subject to applicable law, the purposes for which we use and process Personal Data, and the legal basis for such processing, are set forth below. Making press announcements and other documents
Water
Republic, El
NEXTPOINT THERAPEUTICS, INC. Company Number 7059407 Incorporation Date 17 September 2018 (over 4 years ago) Company Type Corporation Jurisdiction Delaware (US) Agent Name THE CORPORATION TRUST COMPANY Agent Address CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, New Castle, DE, 19801 Directors / Officers THE CORPORATION TRUST COMPANY, agent KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1.